Logo image of UCB.BR

UCB SA (UCB.BR) Stock Overview

EBR:UCB - BE0003739530 - Common Stock

206.9 EUR
+2.3 (+1.12%)
Last: 9/5/2025, 7:00:00 PM

UCB.BR Key Statistics, Chart & Performance

Key Statistics
52 Week High208.5
52 Week Low129.35
Market Cap40.24B
Shares194.51M
Float119.35M
Yearly Dividend1.36
Dividend Yield0.48%
EPS(TTM)6.42
PE32.23
Fwd PE21.35
Earnings (Next)02-25 2026-02-25/amc
IPO01-02 1987-01-02
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


UCB.BR short term performance overview.The bars show the price performance of UCB.BR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10 15 20 25

UCB.BR long term performance overview.The bars show the price performance of UCB.BR in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150

The current stock price of UCB.BR is 206.9 EUR. In the past month the price increased by 12.14%. In the past year, price increased by 28.99%.

UCB SA / UCB Daily stock chart

UCB.BR Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY.DE ELI LILLY & CO 44.84 588.70B
1LLY.MI ELI LILLY & CO 44.78 587.85B
ZEG.DE ASTRAZENECA PLC 18.4 432.52B
JNJ.DE JOHNSON & JOHNSON 17.77 367.61B
RHO.DE ROCHE HOLDING AG-BR 14.74 250.06B
NOT.DE NOVARTIS AG-REG 14.78 214.61B
NOV.DE NOVO NORDISK A/S-B 14.08 209.02B
SAN.PA SANOFI 10.53 193.90B
SNW.DE SANOFI 10.53 193.90B
1SAN.MI SANOFI 10.52 193.75B
1MRKX.MI MERCK & CO. INC. 11.06 182.59B
6MK.DE MERCK & CO. INC. 10.91 180.09B

About UCB.BR

Company Profile

UCB logo image UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,378 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

Company Info

UCB SA

Allee de la Recherche, 60

Anderlecht BRUXELLES-CAPITALE BE

Employees: 9215

UCB Company Website

UCB Investor Relations

Phone: 3225599999

UCB SA / UCB.BR FAQ

What is the stock price of UCB SA today?

The current stock price of UCB.BR is 206.9 EUR. The price increased by 1.12% in the last trading session.


What is the ticker symbol for UCB SA stock?

The exchange symbol of UCB SA is UCB and it is listed on the Euronext Brussels exchange.


On which exchange is UCB.BR stock listed?

UCB.BR stock is listed on the Euronext Brussels exchange.


What is the price forecast or stock price prediction for UCB SA stock?

25 analysts have analysed UCB.BR and the average price target is 224.8 EUR. This implies a price increase of 8.65% is expected in the next year compared to the current price of 206.9. Check the UCB SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is UCB SA worth?

UCB SA (UCB.BR) has a market capitalization of 40.24B EUR. This makes UCB.BR a Large Cap stock.


How many employees does UCB SA have?

UCB SA (UCB.BR) currently has 9215 employees.


What are the support and resistance levels for UCB SA (UCB.BR) stock?

UCB SA (UCB.BR) has a support level at 201.26. Check the full technical report for a detailed analysis of UCB.BR support and resistance levels.


Is UCB SA (UCB.BR) expected to grow?

The Revenue of UCB SA (UCB.BR) is expected to grow by 18.48% in the next year. Check the estimates tab for more information on the UCB.BR EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy UCB SA (UCB.BR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does UCB SA (UCB.BR) stock pay dividends?

UCB SA (UCB.BR) has a dividend yield of 0.48%. The yearly dividend amount is currently 1.36. Check the full fundamental report for a detailed analysis of UCB.BR dividend history, reliability and sustainability.


When does UCB SA (UCB.BR) report earnings?

UCB SA (UCB.BR) will report earnings on 2026-02-25, after the market close.


What is the Price/Earnings (PE) ratio of UCB SA (UCB.BR)?

The PE ratio for UCB SA (UCB.BR) is 32.23. This is based on the reported non-GAAP earnings per share of 6.42 and the current share price of 206.9 EUR. Check the full fundamental report for a full analysis of the valuation metrics for UCB.BR.


UCB.BR Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to UCB.BR. When comparing the yearly performance of all stocks, UCB.BR is one of the better performing stocks in the market, outperforming 89.3% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

UCB.BR Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to UCB.BR. UCB.BR has an average financial health and profitability rating.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

UCB.BR Financial Highlights

Over the last trailing twelve months UCB.BR reported a non-GAAP Earnings per Share(EPS) of 6.42. The EPS increased by 75.41% compared to the year before.


Industry RankSector Rank
PM (TTM) 19.45%
ROA 7.75%
ROE 13.76%
Debt/Equity 0.29
Chartmill High Growth Momentum
EPS Q2Q%68.9%
Sales Q2Q%24.94%
EPS 1Y (TTM)75.41%
Revenue 1Y (TTM)25.56%

UCB.BR Forecast & Estimates

25 analysts have analysed UCB.BR and the average price target is 224.8 EUR. This implies a price increase of 8.65% is expected in the next year compared to the current price of 206.9.

For the next year, analysts expect an EPS growth of 50.88% and a revenue growth 18.48% for UCB.BR


Analysts
Analysts79.2
Price Target224.8 (8.65%)
EPS Next Y50.88%
Revenue Next Year18.48%

UCB.BR Ownership

Ownership
Inst Owners38.65%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A